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In Brief
WHIM syndrome is an inherited
immunodeficiency caused by overactivity
of CXCR4, a receptor controlling
production and distribution of leukocytes
in bone marrow and blood. We identified
a WHIM patient cured by chromothripsis
(chromosome shattering) that fortuitously
deleted the abnormal copy of the CXCR4
gene in a single hematopoietic stem cell,
which then took over the bone marrow
and restored normal immune function.
This experiment of nature suggests that
partial CXCR4 inactivationmight enhance
engraftment of bone marrow in patients
requiring transplantation.
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Chromothripsis is a catastrophic cellular event
recently described in cancer in which chromosomes
undergo massive deletion and rearrangement. Here,
we report a case in which chromothripsis spontane-
ously cured a patient with WHIM syndrome, an
autosomal dominant combined immunodeficiency
disease caused by gain-of-function mutation of the
chemokine receptor CXCR4. In this patient, deletion
of the disease allele, CXCR4R334X, as well as 163
other genes from one copy of chromosome 2
occurred in a hematopoietic stem cell (HSC) that re-
populated the myeloid but not the lymphoid lineage.
In competitive mouse bone marrow (BM) transplan-
tation experiments, Cxcr4 haploinsufficiency was
sufficient to confer a strong long-term engraftment
advantage of donor BM over BM from either wild-
type or WHIM syndrome model mice, suggesting a
potential mechanism for the patient’s cure. Our find-
ings suggest that partial inactivation of CXCR4 may
have general utility as a strategy to promote HSC
engraftment in transplantation.
INTRODUCTION
WHIM syndrome is an autosomal dominant combined primary
immunodeficiency disease caused by mutations in the chemo-
kine receptor CXCR4 (Hernandez et al., 2003). The term
‘‘WHIM’’ is an acronym for the main manifestations of the dis-686 Cell 160, 686–699, February 12, 2015 ª2015 Elsevier Inc.ease: warts, hypogammaglobulinemia, recurrent infections,
and myelokathexis; myelokathexis refers to impaired egress of
mature neutrophils from bone marrow causing neutropenia
(Wetzler et al., 1990; Zuelzer, 1964). Most patients with WHIM
syndrome are actually panleukopenic, with severely reduced
peripheral blood B cells but less severe reductions in peripheral
blood T cells and monocytes (McDermott et al., 2011). The
signature pathogen in WHIM syndrome is human papillomavirus
(HPV), which causes warts that cannot be controlled with stan-
dard medical treatment and may progress to cancer (Al Ustwani
et al., 2014; Beaussant Cohen et al., 2012; Dotta et al., 2011;
Kawai and Malech, 2009). Recurrent bacterial infections also
occur, mainly in the sinopulmonary tract, oral cavity, ear, skin,
and soft tissue, where chronic complications may arise, espe-
cially bronchiectasis and hearing loss. Prophylactic antibiotics,
IVIg and G-CSF are often used to reduce the incidence of infec-
tions; however, their precise efficacy has not been established
(Al Ustwani et al., 2014; Beaussant Cohen et al., 2012; Dotta
et al., 2011; Kawai and Malech, 2009). In contrast, safety and
preliminary evidence of clinical efficacy has recently been re-
ported from Phase I studies of the specific CXCR4 antagonist
plerixafor (Mozobil, AMD3100) (Dale et al., 2011; McDermott
et al., 2011, 2014). Spontaneous remission or cure of WHIM syn-
drome has not been previously reported.
WHIM mutations of CXCR4 increase signaling because they
disrupt negative regulatory elements in the carboxy-terminus,
thereby exaggerating the normal hematopoietic functions of
the receptor (Haribabu et al., 1997; Signoret et al., 1998; Venka-
tesan et al., 2003). CXCR4 is normally expressed by most leuko-
cytes and has one ligand, CXCL12 (Bachelerie et al., 2014; Bleul
et al., 1996), which is constitutively expressed at high levels by
stromal cells in the bone marrow and normally mediates HSC
retention in bone marrow niches (Broxmeyer et al., 2003b; Brox-
meyer et al., 2005; Dar et al., 2006; Sugiyama et al., 2006; Zou
et al., 1998). In addition, CXCR4 signaling promotes hematopoi-
etic stem cell (HSC) quiescence, homing to bone marrow from
blood and differentiation into committed myeloid progenitors
(Broxmeyer et al., 2003a, 2003b; Kawai et al., 2007; Nie et al.,
2008; Sugiyama et al., 2006).
Chromothripsis refers to multiple clustered genetic rearrange-
ments and deletions affecting one or a few chromosomes (Ste-
phens et al., 2011). The abnormalities are thought to occur all
at once in a single cell, which then presumably either dies or ac-
quires a growth advantage, depending on the genes affected
(Stephens et al., 2011). Accordingly, chromothripsis was first
identified by whole genome sequencing of cancer cell lines
and has been reported to affect 2% of all cancers (Jones and
Jallepalli, 2012), as well as one patient with a severe congenital
cognitive syndrome (Kloosterman et al., 2011). Criteria for chro-
mothripsis include (1) clustering of breakpoints in limited areas of
one or several chromosomes with large intervening regions of
normal sequence, (2) copy number states that suddenly oscillate
between areas of normal heterozygosity and loss of heterozy-
gosity, and (3) rearrangements affecting a single haplotype
with multiple fragments rearranged in random orientation and
order (Korbel and Campbell, 2013). Here, we describe chromo-
thriptic deletions of one copy of chromosome 2, including dele-
tion of the disease allele CXCR4R334X, in a patient with WHIM
syndrome that resulted in cure of the disease.
RESULTS
Cure of a Patient with WHIM Syndrome
The index patient, designated WHIM-09, is a white female who
presented at age 58 to the NIH requesting evaluation for herself
and two of her three daughters, designated WHIM-10 (age 21)
and WHIM-11 (age 23) (Figure 1A). Both daughters had a history
of recurrent infections since early childhood, multiple cutaneous
warts, panleukopenia, and hypogammaglobulinemia, and there-
fore fulfilled all the clinical criteria for WHIM syndrome. In
contrast, WHIM-09 reported that from childhood through age
38 she had hadmany serious infections, often requiring hospital-
ization, but then none in the 20 subsequent years, and that she
had had confluent warts on her hands that spontaneously
resolved also in her 30s (Figure 1B). Moreover, we found that
at the time of presentation, WHIM-09 was not neutropenic, but
instead had amild leukocytosis, including an absolute neutrophil
count (ANC) and absolute monocyte count (AMC) that were 2-
fold greater than the upper limit of normal; in contrast, the abso-
lute lymphocyte count (ALC) was within normal limits. The past
medical history revealed that WHIM-09 was in fact the first pa-
tient ever described with myelokathexis, the key hematopatho-
logic feature in WHIM syndrome, reported in two articles pub-
lished in The New England Journal of Medicine (NEJM) in 1964
(Krill et al., 1964; Zuelzer, 1964). She underwent a therapeutic
splenectomy at age 9 for the possibility of autoimmune neutro-
penia, which was ineffective. There is no evidence that her par-
ents or siblings had WHIM syndrome. Thus, the history and clin-
ical evidence were compatible with a WHIM mutation occurring
de novo in patient WHIM-09, autosomal dominant transmissionto two of her three daughters, and spontaneous and durable
complete clinical remission in WHIM-09 in her fourth decade of
life (Figure 1A).
To evaluate potential mechanisms for clinical remission, we
first graphed all available white blood cell counts for WHIM-09,
including those previously published in the NEJM (Figure 1C).
Consistent with the clinical history, this revealed severe neutro-
penia at least from age 9 that was unaffected by splenectomy
but that began to resolve spontaneously early in the fourth
decade of life, rising slowly over time to a newand stable baseline
slightly above the upper limit of normal. The AMC followed the
same time course, whereas, interestingly, the ALC did not, start-
ing in the normal range for healthy individuals as a child then
increasing inconsistently and only slightly as an adult. Neverthe-
less, when lymphocyte subsets were examined in detail, all B cell
subsets and both naive CD4+ and CD8+ T cell subsets were
below the lower limit of normal (Table 1), as they were in both
daughters and most other patients reported with WHIM syn-
drome. Consistent with this, WHIM-09 was slightly hypogamma-
globulinemic at the time of presentation to NIH with IgG =
535mg/dl (normal range, 642–1,730 mg/dl). In contrast, memory
CD4+ and CD8+ T cell subsets were elevated in WHIM-09, but
deficient in both daughters. Unfortunately, WHIM-09’s archival
lymphocyte subset values from the years when she fulfilled the
clinical criteria for WHIM syndrome were not available.
We considered myeloid leukemia or a possible pre-leukemic
state as a cause of her mild leukocytosis; however, the patient
was clinically well over this20-year time span when her neutro-
phils and monocytes were increasing, and her blood smear and
bone marrow histopathology at the NIH were not consistent with
these diagnoses (Figure 1D); moreover, specific testing for B and
T cell clonality as well as for BCR-ABL and JAK mutations were
negative (see Extended Experimental Procedures for details).
Consistent with her apparent 20-year complete remission of
WHIM syndrome by clinical criteria, her bone marrow did not
present the characteristic features of the disease (increased
myeloid:erythroid ratio, neutrophil vacuolization, eyeglass nuclei
in neutrophils), which were, however, all present in her bone
marrow histopathology reported in the NEJM in 1964, shown
again here for comparison, with permission, in Figure 1D
(Zuelzer, 1964). Since the patient reported she had undergone
several prior surgeries and blood transfusions, we tested her
blood for evidence of allogeneic chimerism and found none
(data not shown). Thus, although the patient appeared to be clin-
ically cured, she was hematologically mosaic, with sustained
spontaneous correction of neutropenia, monocytopenia, and
myelokathexis, and continued deficiency of B and naive T lym-
phocytes in the blood.
Patient WHIM-09 Is a Genetic Mosaic for CXCR4R334X,
the Most Common Mutation Causing WHIM Syndrome
We next genotyped whole blood DNA from family members us-
ing an established PCR-BstUI restriction fragment length poly-
morphism (PCR-RFLP) assay for the most common mutation
in WHIM syndrome, CXCR4R334X. Both affected daughters
(WHIM-10 and WHIM-11) tested positive, whereas the unaf-
fected husband and third unaffected daughter tested negative.
Surprisingly, two independent whole blood samples fromCell 160, 686–699, February 12, 2015 ª2015 Elsevier Inc. 687
Figure 1. Long-Term Clinical Remission of WHIM Syndrome and Evidence for Somatic Mosaicism in Patient WHIM-09
(A) Family pedigree. Squares, males; circles, females; shaded symbols, WHIM syndrome; arrow, index patient WHIM-09.
(B) Spontaneous and complete remission of warts in patient WHIM-09. According to patient WHIM-09, through her fourth decade of life she had had extensive
warts on her hands, similar to her daughters (illustrated here for 24-year-old daughter WHIM-11), that spontaneously resolved.
(C) Spontaneous sustained correction of neutropenia and monocytopenia in patient WHIM-09. WBC, white blood cell count; ANC, absolute neutrophil count;
AMC, absolute monocyte count; ALC, absolute lymphocyte count. Arrows indicate age at splenectomy; horizontal lines indicate normal range for each cell type.
Note, x axis is discontinuous to show pre/post splenectomy results more clearly.
(legend continued on next page)
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WHIM-09, in which the leukocyte content was composedmostly
of neutrophils and monocytes (Figures 1E and 1F), also tested
negative for the mutation. In contrast, DNA from WHIM-09
PBMCs, which were composed mostly of lymphocytes, as well
as from a lymphoblastoid cell line generated from WHIM-09
PBMCs both tested positive for CXCR4R334X (Figure 1E). The
mutation was also not detectable by direct sequencing of whole
blood cell DNA from WHIM-09, whereas whole blood cell sam-
ples from both daughters, WHIM-10 and WHIM-11, were both
positive (Figure 1F). In contrast, DNA samples from a cheek
swab and fibroblasts cultured from a skin biopsy from WHIM-
09 were both heterozygous for CXCR4R334X (Figures 1E and
1G), defining her as a somatic genetic mosaic. A WHIM
pedigree with germ-line/somatic genetic mosaicism, where the
mother of two affected children was hematologically normal,
has previously been described (Hernandez et al., 2003), but
was unlikely to apply to WHIM-09 since she had been markedly
symptomatic with severe neutropenia and myelokathexis as a
child and cutaneous warts as an adult (Krill et al., 1964; Zuelzer,
1964). Therefore, we investigated whether a genetic reversion
had occurred.
Chromothripsis as the Mechanism for Genetic
Mosaicism in Patient WHIM-09
The PCR-RFLP assay and DNA sequencing results may both be
explained by either reversion or deletion in patient leukocytes of
the mutant nucleotide that defines the CXCR4R334X allele. To
address this, we first performed cytogenetic analysis of bone
marrow cells. In all 20 metaphase cells examined, one copy of
chromosome 2, whereCXCR4 is located, was acrocentric rather
than submetacentric and was significantly shorter than its
normal homolog (Figure 2A). All other chromosomes appeared
normal. In addition to deletions, the banding pattern of the
abnormal chromosome 2 suggested the presence of inversions.
Fluorescence in situ hybridization (FISH) revealed that the
anaplastic lymphoma receptor tyrosine kinase (ALK) gene, at
2p23 on the normal chromosome 2, was on the long arm of the
abnormal chromosome 2 (Figure 2B). FISH also demonstrated
that the abnormal chromosome 2 had a portion of the centro-
mere inverted into the long arm and the N-myc gene (MYCN),
normally on 2p24, was absent (Figure 2C). Almost all of the inter-
phase bone marrow cells with polymorphic nuclei, consistent
with neutrophils, had the abnormal hybridization patterns of
the abnormal chromosome 2 (Figure 2C), whereas cells with
round nuclei had a significantly lower percentage of the
abnormal chromosome (data not shown). An immunohistochem-
ical stain of ALK activity on a bone marrow core biopsy section(D) Normalization of bone marrow pathology in patient WHIM-09. A representative
shown for the index patient WHIM-09 in 1963 (Zuelzer, 1964) (reproduced with
eyeglass nuclei in neutrophils.
(E) PCR-BstUI restriction fragment length polymorphism (BstUI) analysis of genom
PBMC, peripheral blood mononuclear cells; Fb, fibroblast; LCL, lymphoblastoid
causes WHIM syndrome.
(F) Sanger DNA sequencing analysis of whole blood DNA for affected family mem
mutation CXCR4R334X (1,000 C/ T). Blue, C; Red, T; Fb, fibroblast; PMN, polym
(G) Sanger DNA sequencing analysis of DNA frompurified peripheral blood neutrop
patient WHIM-09 in the same region as (F).did not reveal abnormal activation of the enzyme despite its
abnormal chromosomal location (Figure S1).
To define the chromosomal abnormalities with greater reso-
lution, microarray was performed using patient bone marrow
cell and cultured fibroblast DNA. This revealed that the
abnormal chromosome 2 was 35 Mb shorter than usual due
to seven large deletions (Figure S2A), as demonstrated by
loss of heterozygosity in these regions and by an abrupt
change in the relative copy number from 2 to 1. One of the de-
letions involved the MYCN gene, confirming the FISH results. In
addition, one of the deletions included the position of the
CXCR4 gene (Figure S2B). This had made the patient hemizy-
gous for CXCR4 in cells having the abnormal chromosome 2
with loss of the CXCR4R334X mutation as well as loss of one
copy of 163 other annotated genes (Table S1). Thus, develop-
ment of hemizygosity of CXCR4, with only the wild-type copy
remaining, explained why the CXCR4R334X mutation was not
detectable in neutrophil DNA by either DNA sequencing or
PCR-RFLP. However, this potentially fortuitous deletion was
clearly only a small part of a much larger and more complex
genetic event.
We next performed whole genome sequencing (WGS)
for single nucleotide definition of the event, comparing
blood neutrophil and skin fibroblast DNA from WHIM-09
to each other and to the standard human genome sequence
in GenBank (version hg19). We obtained an average of 403
coverage of both samples (database of Genotypes and
Phenotypes [dbGaP] accession number phs000856.v1.p1.
[http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000856.v1.p1]) and an analysis was performed
to locate the DNA reads that had homology with multiple
distinct areas of chromosome 2. This technique allowed pre-
cise base pair level identification of the inversions and deletions
that had occurred on one copy of chromosome 2 (Table S2).
No other large deletions or inversions were detected in the
genome.
The changes seen in the microarray were confirmed by WGS
but were actually more complex than had been initially sus-
pected. The derivative chromosome was composed of 18 re-
maining pieces arranged in random orientation and in a
random order, characteristic of chromothripsis (Figure 3A). A
circular plot of the connections revealed by paired end WGS
of the neutrophil DNA is shown in Figure 3B. The abnormal de-
rivative chromosome, modeled using the breakpoints and con-
nections (Figure 3C), revealed a predicted structural banding
pattern that was identical to what was observed by cytoge-
netic analysis. We also developed primer pairs spanning fourhigh magnification (5003) Wright-Giemsa stain of the bone marrow aspirate is
permission) and in 2013 at ages 9 and 59, respectively. Arrows in left image,
ic DNA. HD, healthy donor; WHIM-09, index patient; Cheek, cheek swab cells;
cell line; WB, whole blood; WT, wild-type allele; WHIM, CXCR4R334X allele that
bers in the region near nucleotide position 1,000 (vertical line), the site of WHIM
orphonuclear leukocyte (PMN).
hils, cells obtained from a buccal swab (cheek) and cultured skin fibroblasts for
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Table 1. Distribution of Leukocyte Subsets in the Peripheral
Blood of Index Patient WHIM-09 in Clinical Remission from
WHIM Syndrome and Her Two Affected Daughters, WHIM-10 and
WHIM-11
Leukocyte Subset WHIM-09 WHIM-10 WHIM-11
Normal Adult
Reference
Rangec
Neutrophil 9,980a 380b 530b 1,560–6,130
CD3+ T cell 1,736 382b 218b 714–2,266
CD4+ T cell 1,389 317b 155b 359–1,565
CD4+ CD45RA+
naive T cell
211b 44b 12b 454–733
CD4+ CD45RO+
memory T cell
1,178a 273 143b 219–1,048
CD8+ T cell 222 41b 45b 178–853
CD8+ CD45RA+
naive T cell
44b 22b 14b 231–371
CD8+ CD45RO+
memory T cell
178a 19b 31b 57–130
CD3 CD56+ NK
cell
1,270a 32b 51b 126–729
CD19+ B cell 18b 5b 10b 61–329
CD19+ CD27+
memory B cell
2b 1b 1b 12–68
CD19+ CD27
B cell
16b 4b 9b 90–176
CD19+ CD27 IgD+
IgM+ transitional/
naive B cell
12b 3b 4b 42–85
CD19+ CD27 IgD
IgM+ immature
B cell
4 1b 1b 2–10
CD14+ CD16
classical monocyte
1,344a 35b 117b 371–539
CD14+ CD16+
inflammatory
monocyte
235a 5b 23 14–30
Data are presented as absolute numbers of cells having the indicated
immunophenotype per microliter of whole blood.
aValue above the upper limit of normal.
bValue below the lower limit of normal.
cBased on the values of 11–40 healthy blood donors seen at the NIH
Clinical Center.of the unique chromothriptic boundaries and demonstrated
experimentally that they generated the predicted rearranged
product from WHIM-09 neutrophil DNA but not from healthy
donor DNA (data not shown). By analyzing the rearrangement
breakpoints for the creation of novel fusion genes, we found
two possibilities, fusions of MFSD2B with LOC285000 and
POTEKP with NCKAP5 (Figure S3); however, these genes are
unlikely to be expressed or functional because each lacks a
promoter and transcription initiation site, and major regions
of the potentially fused genes are deleted. Thus, the most likely
explanation for the patient’s clinical improvement was haploin-
sufficiency for one or more of the 164 genes affected by
chromothripsis.690 Cell 160, 686–699, February 12, 2015 ª2015 Elsevier Inc.Myeloid/Lymphoid Mosaicism Established by
Chromothripsis in an HSC from Patient WHIM-09
Chromothripsis-specific primers did not generate a detectable
product by PCR when DNA prepared from the archival spleen
sample from patient WHIM-09 was amplified, suggesting that
the chromothriptic event occurred after age 9, when splenec-
tomy was performed, but before age 35, when the rise in
WBC was already underway (Figure 4A). The emergence of
uniformly chromothriptic neutrophils, as suggested by WGS,
PCR, and bone marrow cytogenetics and FISH, implied that
at least some patient HSCs must also be chromothriptic. We
verified this with CD34+ leukocytes cultured from peripheral
blood, as well as with CD38CD90+CD45RA HSCs FACS-
sorted from patient bone marrow (Figures 4B, 4C, and S4)
that both appeared to be markedly deficient in or lack the
CXCR4R334X allele by the BstUI PCR-RFLP assay. Consistent
with this, CD38+CD135+CD45RA common myeloid precursor
cells (CMP) and CD38+CD135+CD45RA+ granulocyte-mono-
cyte precursor cells (GMP) sorted from patient bone marrow
also lacked the CXCR4R334X allele by the PCR-RFLP assay,
whereas FACS-sorted CD45+ CD34+ CD38+ CD10+ common
lymphoid precursors (CLP) remained CXCR4+/R334X (Figure 4D,
lower panel). This pattern was confirmed by PCR using chro-
mothripsis-specific primers and DNA from HSCs, CMPs, and
CLPs (Figure 4D, upper panel). Consistent with this, we found
that all mature myeloid cell types tested in both blood and
bone marrow lacked or were markedly deficient in the
CXCR4R334X WHIM allele, whereas all mature lymphoid cell
types tested in peripheral blood and bone marrow were het-
erozygous CXCR4+/R334X (Figures 4B and 4C). This aligns
with the cytogenetic results presented in Figure 2C. Further,
we found 100% of EBV-transformed B cell lines (n = 10) pre-
pared from patient blood lacked the chromothriptic chromo-
some (data not shown). As expected, erythroid precursors,
which derive from CMPs, also lacked the CXCR4R334X
allele as demonstrated by BstUI PCR-RFLP analysis of Burst
Forming Unit-Erythroid (BFU-E) colonies generated from pa-
tient CD34+ cells cultured from PBMCs ex vivo (Figure 4E).
Thus, the combined evidence suggests that an HSC under-
went chromothripsis and selectively repopulated the myeloid
lineage (including the erythroid lineage), but not the lymphoid
lineage (Figure 4F).
Cxcr4 Haploinsufficiency Enhances Engraftment during
Bone Marrow Transplantation
To test whether deletion of the disease allele CXCR4R334X
alone, and not any of the other 163 genes deleted by chromo-
thripsis would be sufficient to confer a selective advantage to
an HSC in the context of WHIM syndrome, we performed
competitive repopulation experiments using a mouse model
of WHIM syndrome (Cxcr4+/S338X), hemizygous Cxcr4 mice
(Cxcr4+/o, the same as the HSC and myeloid cell CXCR4 geno-
type of patient WHIM-09), and wild-type (Cxcr4+/+) mice as
donors and recipients. Leukocytes from these strains were
specifically marked with either CD45.1 or CD45.2 or both, al-
lowing tracking of transplanted donor cell fate in vivo by
FACS. When 2.5 3 106 total donor bone marrow cells from
both Cxcr4+/S338X and Cxcr4+/o mice were mixed together in
Figure 2. Massive Deletion and Rearrangement of
One Copy of Chromosome 2, the Location of
CXCR4, in Patient WHIM-09
Cytogenetics and fluorescence in situ hybridization (FISH)
analyses were performed on cultured bone marrow cells.
(A) Cytogenetics. Karyogram showing a short acrocentric
chromosome 2 (arrow) with abnormal banding pattern
suggesting deletions and inversions observed in all 20
metaphase cells analyzed from bone marrow.
(B) FISH with intact ALK break apart probe (Abbott
Molecular) signal at 2p23 on normal chromosome 2 and on
long arm of abnormal chromosome 2 (der 2).
(C) FISH with MYCN and CEP 2 probe set (Abbott Molec-
ular). Left: metaphase cell showing the normal chromo-
some 2 with intact centromere signal (red) and MYCN
signal (green) at 2p24. The abnormal chromosome 2 has a
portion of its centromere inverted into the long arm splitting
the red signal; the green MYCN signal is absent. Right:
polymorphonuclear and round interphase nuclei showing
the abnormal hybridization pattern with one green MYCN
signal and three red CEP 2 signals. One of the red signals is
smaller than the other two and is close to one of them. See
also Figure S1.
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Figure 3. Chromothripsis as the Mechanism for Loss of CXCR4R334X in Patient WHIM-09
Purified neutrophil and cultured skin fibroblast DNA from patient WHIM-09 was isolated and subjected to whole genome sequencing with paired-end analysis.
(A) Linear non-proportional plot of the abnormal copy of chromosome 2 in patient WHIM-09 labeled from the p arm telomere (0) to the q arm telomere (243) in
megabases with the 18 remaining pieces arranged in their numeric order (top). Connections between these pieces are depicted by the curved lines. Note that
some connections were poorly defined because of the involvement of repetitive centromeric sequence (black lines). The order and orientation of the 18 remaining
pieces in the derivative chromosome are indicated at the bottom.
(B) Circos plot of chromosome 2 and its normal Giemsa cytogenetic banding pattern labeled from the p arm telomere (0) to the q arm telomere (240) in
megabases. Large pieces of chromosome 2 were missing from patient WHIM-09 neutrophil DNA and the 18 remaining pieces were arranged in random order.
Connections between these pieces and their orientation (inset) are depicted by the colored lines. See Figure S2 and Tables S1 and S2 for additional details. Note
that two connections were poorly defined because of the involvement of repetitive centromeric sequence. The inner circular trace is the copy number variation
data derived frommicroarray analysis (Figures S2A and S2B). Note that the sites of connections derived from the paired-end sequencing analysis closely match
the sites where copy number variation abruptly falls from 2 to 1. The location of CXCR4 is indicated at lower left.
(C) Derivative chromothriptic chromosome 2. Ideogram of intact chromosome 2 (left) and a model of the Giemsa cytogenetic banding pattern and the order and
orientation of the 18 pieces with the deletions called by microarray shaded in yellow (right) are shown. The resultant remaining chromosome 2 banding pattern
predicted bywhole genome sequencing closely matches that seen by cytogenetic analysis. Note the location ofCXCR4 at 2q22.1 in one of the deleted segments.
See also Figure S3.
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Figure 4. Chromothriptic CXCR4-Haploinsufficient HSC Replacement of the Myeloid Lineage, but Not the Lymphoid Lineage, Is Associated
with Clinical Remission in Patient WHIM-09
(A–E) Representative results from a BstUI PCR-restriction fragment length polymorphism assay (BstUI), designed to distinguish the wild-type CXCR4 allele (WT)
from the CXCR4R334X WHIM allele (WHIM), as well as from a PCR assay specific for the chromothriptic chromosome (13–16 Jxn). PCR was performed on DNA
obtained from the indicated donor leukocyte subsets purified either from blood using magnetic bead purification (B and E) or from a bone marrow aspirate using
flow cytometric sorting (C and D). DNA was also prepared from archived WHIM-09 spleen and compared with peripheral blood PMN DNA (A), as well as from
Burst-forming Unit-Erythroid colonies and compared with blood leukocyte subsets (E). WHIM-09, index patient; HD, healthy donor; Spl, spleen; PMN, poly-
morphonuclear leukocytes; 13–16 Jxn, PCR product specific for the chromothriptic junction between segments 13 and 16 of the chromothriptic chromosome of
patientWHIM-09; PBMC, peripheral bloodmononuclear cells; CD4, purified CD4+ T cells; CD8, purified CD8+ T cells; CD19 purified CD19+ B cells; CD56, purified
CD56+ natural killer cells; CD14, purified CD14+ monocytes; CD34, purified CD34+ hematopoietic cells; CD3, purified CD3+ T cells; CD15, purified CD15+
neutrophils; CD16, purified CD16+ neutrophils; HSC, hematopoietic stem cells; CLP, common lymphoid precursor; CMP, common myeloid precursor;
GMP, granulocyte/monocyte precursor MEP, megakaryocyte-erythroid precursor; BFU-E, Burst-forming Unit-Erythroid; CXCR4,CXCR4 amplicon not digested
with BstUI.
(F) Summary of myeloid/lymphoid mosaicism for CXCR4R334X in patient WHIM-09. The immunophenotype used to purify each cell type from enriched
CD34+CD45+ cells is summarized next to each cell type shown. Red, negative for CXCR4R334X; green, positive for CXCR4R334X; asterisks, purified cell types
directly analyzed by PCR-RFLP for the WHIM mutation.
See also Figure S4.equal proportions (50%:50%) and transplanted into lethally
irradiated Cxcr4+/+ recipients, by day 105 post-transplantation
the percentage of Cxcr4+/S338X neutrophils, monocytes, and B
cells detectable in the peripheral blood had declined to 5%,
whereas the percentage of each of the corresponding Cxcr4+/o
leukocyte subsets had increased to 95% (Figure 5A). The
rate at which the proportion of donor-derived blood cellsdiverged in frequency from the input ratio of 50:50 occurred
in two phases, a rapid early phase within 2 weeks and a
slow late phase evident by 2 weeks after transplantation. The
inflection point could be earlier than 2 weeks, since this is
the first time point when data were collected to allow for recov-
ery after transplantation. Importantly, there was no difference
in the baseline HSC frequency in bone marrow for Cxcr4+/oCell 160, 686–699, February 12, 2015 ª2015 Elsevier Inc. 693
Figure 5. Cxcr4 Haploinsufficiency Enhances HSC Engraftment during Mouse Bone Marrow Transplantation
Two types of competitive bonemarrow transplantation experiments were performed: (A)Cxcr4+/o versusCxcr4+/S338X (mousemodel ofWHIM syndrome), and (B)
Cxcr4+/o versus Cxcr4+/+. (i) Experimental design. (ii) Representative flow cytometry plots demonstrating the relative contributions of CD45 congenic markers in
mixed donor bone marrow prior to transplantation (left panel) and in blood after bone marrow transplantation (right panel) in a single mouse. (iii) Cell frequency
data for the leukocyte subsets indicated at the top of each panel, presented as the mean ± SEM percentage (%) of total donor-derived cells for each subset (n =
10 mice per data point). SEM was <5% of the mean in all cases and therefore is not visible for most data points. Results were verified in one and two additional
independent experiments for (A) and (B), respectively.
See also Figure S5.and Cxcr4+/S338X donor mice, so the number of HSCs trans-
planted was similar (Figure S5). Since the ANC in the
peripheral blood of Cxcr4+/S338X donor mice is only 50%
less than the corresponding value in both Cxcr4+/+ mice (Bala-694 Cell 160, 686–699, February 12, 2015 ª2015 Elsevier Inc.banian et al., 2012; J.-L.G., M.S., E.Y., and P.M.M., data not
shown ) and Cxcr4+/o mice (J.-L.G., unpublished data), the
extreme skewing of these transplantation results in the blood
suggested that hemizygous Cxcr4 (Cxcr4+/o) HSCs may have
a selective advantage over WHIM (Cxcr4+/S338X) HSCs for
engraftment in this system. Consistent with this, in the bone
marrow, as in the blood, we observed a greater content of
mature Cxcr4+/o leukocytes compared to mature Cxcr4+/S338X
leukocytes (data not shown). No difference was observed for
the frequencies of Cxcr4+/o and Cxcr4+/S338X T cells in the
blood, presumably owing to homeostatic proliferation of
mature T cells present in donor bone marrow transferred into
irradiated hosts.
To test whether there might be a general selective advantage
ofCxcr4 hemizygosity in transplantation, we performed compet-
itive repopulation experiments by mixing 2.5 3 106 total donor
bone marrow cells each from Cxcr4+/+ and Cxcr4+/o mice and
transplanting the mixture into lethally irradiated Cxcr4+/+ recipi-
ents. The baseline HSC frequency in bone marrow was the
same for Cxcr4+/o and Cxcr4+/+ donor mice (Figure S5). In this
case, the input ratio was skewed slightly in favor of the
Cxcr4+/+ cells over the Cxcr4+/o cells (58%:42%). Nevertheless,
by day 303 post-transplantation, when the animals were sacri-
ficed, the percentage of Cxcr4+/+ neutrophils, monocytes and
B cells detectable in the peripheral blood had declined to less
than15%, whereas the percentage of each of the correspond-
ing Cxcr4+/o leukocyte subsets had increased to 85% with
similar kinetics as for the competition with Cxcr4+/S338X bone
marrow (Figure 5B). The same effect was observed whether
the irradiated recipient mouse was CD45.1, CD45.2, or Cxcr4+/o
(data not shown) and whether the donor bone marrows were
depleted of lineage-positive cells (Figure S6).
To investigate the mechanism for the apparent competitive
advantage of Cxcr4+/o over Cxcr4+/+ bone marrow cells for re-
constituting the blood, we first measured the proliferative status
of the corresponding HSCs in vivo by BrdU incorporation early
after transplantation (day 7) (Figure 6A). The results indicated
20% greater frequency of BrdU+ Cxcr4+/o HSCs as compared
to Cxcr4+/+ HSCs suggesting a proliferative advantage of
Cxcr4+/o HSCs in the bone marrow. To test whether differential
retention of leukocytes in the bone marrow might also
contribute to the skewed distribution of mature leukocytes in
the blood, we sacrificed mice at day 303 after competitive
transplantation with Cxcr4+/o and Cxcr4+/+ bone marrow cells
(the same combination of donor bone marrow cells as were
analyzed in the proliferation experiments). The results showed
that Cxcr4+/o HSCs, HPCs (hematopoietic progenitor cells),
and total CD45+ cells (mostly mature leukocytes) predominated
in the bone marrow by the same 4:1 ratio over the correspond-
ing Cxcr4+/+ cells as was found for mature leukocytes in the
blood. Thus, the predominance of mature Cxcr4+/o over
Cxcr4+/+ leukocytes in the blood of competitively transplanted
mice cannot be simply explained by low retention of mature
Cxcr4+/o leukocytes relative to the retention of mature Cxcr4+/+
leukocytes in the bone marrow. Moreover, the results at this
very late time point clarify that enhanced Cxcr4+/o HSC prolifer-
ation does not result in long-term depletion of HSCs. The fre-
quency distribution of stem and progenitor subtypes was the
same for each genotype, indicating no block to progenitor
cell differentiation (Figure 6B).
Finally, when Cxcr4+/o bone marrow was used in competi-
tive repopulation assays with either Cxcr4+/+ or Cxcr4+/S338X,we found in both cases that the total white blood cell and dif-
ferential counts in the blood post-transplantation were not
significantly altered as compared to reference values for
C57Bl/6J mice (http://phenome.jax.org), suggesting that
Cxcr4+/o genotype does not predispose to myelodysplasia or
leukemia in the setting of this transplantation model (Fig-
ure S7). Moreover, there is no evidence that Cxcr4+/o mice
have a constitutive predisposition to myelodysplasia (data
not shown).
DISCUSSION
Our analysis of this unprecedented experiment of nature in a
single patient provides the first evidence that chromothripsis,
a newly described form of genetic instability, may result in clin-
ical benefit, in particular, cure of an inherited disease. This pa-
tient also provides the second example of chromothripsis
occurring in a stem cell still capable of terminal differentiation,
(Kloosterman et al., 2011) as well as one of the few examples of
spontaneous genetic cure of a Mendelian condition (Hirsch-
horn, 2003).
We use the word ‘‘cure’’ to refer to the patient’s clinical
outcome because she had met all four of the acronymic clinical
criteria diagnostic for WHIM syndrome through her fourth
decade of life, but has fulfilled none except for mild hypogam-
maglobulinemia since then (20 years, to date). Moreover, the
disease allele CXCR4R334X is no longer detectable in key cell
types that drive the disease: HSCs, neutrophils, and mono-
cytes. To our knowledge, patient WHIM-09’s spontaneous
long-term complete remission of warts without treatment is un-
precedented in WHIM syndrome (Al Ustwani et al., 2014; Beau-
ssant Cohen et al., 2012; Kawai and Malech, 2009; Tassone
et al., 2009; Wetzler et al., 1990). Since she remains lympho-
penic (B and naive T lymphocytes), this suggests that the
myeloid arm of the immune system, probably through mono-
cytes or monocyte-derived cells, plays an essential role in
HPV clearance.
The combined evidence suggests that an HSC in WHIM-09
underwent chromothripsis between the second and fourth
decade of life and selectively repopulated the myeloid lineage,
but not the lymphoid lineage. This pattern of hematologic
mosaicism implies that the chromothriptic changes precluded
differentiation of HSCs to CLPs but not to CMPs. Thus, the
mechanism for maintenance of the B cell lineage, which is
WHIM in the patient, is unclear. Possibilities include differenti-
ation from a small population of persistent WHIM HSCs below
the level of detection of our assays, or by differentiation of
self-sustaining or very long-lived WHIM CLPs. In contrast,
the T cell lineage may simply have been maintained by
homeostatic proliferation of the pre-chromothriptic WHIM
T cell repertoire.
Chromothripsis is a complex chromosomal catastrophe that is
thought to occur all at once in one cell (Stephens et al., 2011). If
the affected cell dies, chromothripsis is clinically silent and unde-
tectable, therefore the true frequency with which it occurs
cannot be determined. If the chromothriptic cell acquires a
strong selective advantage, it may emerge as a readily detect-
able, clinically apparent clonal population harboring a singleCell 160, 686–699, February 12, 2015 ª2015 Elsevier Inc. 695
Figure 6. Cxcr4 Haploinsufficiency Enhances HSC Proliferation and Engraftment in a Mouse Bone Marrow Transplantation Model
(A) Proliferation. Donor bone marrow cells with a Cxcr4+/o genotype on a homozygous CD45.2 background were mixed with donor bone marrow cells with a
Cxcr4+/+ genotype on a heterozygous CD45.1/CD45.2 background (47:53) and injected intravenously into a lethally irradiated CD45.1 recipient mouse. Six days
after bone marrow transplantation, each mouse was given 1.25 mg of BrdU intraperitoneally (i.p.). Twenty hours later, the mice were euthanized for HSC pro-
liferation analysis. (i) Gating scheme for BrdU+ HSCs. Bone marrow cells were first gated with CD45.2 (Cxcr4+/o) and CD45.1/CD45.2 (Cxcr4+/+), then HSCs were
gated as Flt3 Lin Sca1+ c-Kit+ (Flt3LSK), which includes long-term and short-term HSCs, and BrdU+ cells were quantitated. (ii) Percentage of BrdU+ HSCs in
each donor. Data are expressed as mean ± SEM from four mice. The experiment was repeated once with similar results.
(B) Long-term engraftment and differentiation. Bone marrow cells from donor mice with a Cxcr4+/o genotype on a CD45.2 background were mixed with bone
marrow cells from donors with a Cxcr4+/+ genotype on a CD45.1 background (42:58) and the mixed cells were injected intravenously into lethally irradiated
recipient mice. Bone marrow was harvested 303 days later. (i) Gating scheme for long-term HSC (LT-HSC: CD34Flt3 Lin Sca1+ c-Kit+), short-term HSC
(ST-HSC: CD34+Flt3 Lin Sca1+ c-Kit+), multipotent progenitors (MPP: CD34+Flt3+ Lin Sca1+ c-Kit+), and common lymphoid progenitors (CLP: IL7ra+ Lin
Sca1low c-Kitlow). (ii) Long-term engraftment. (iii) Differentiation. The distribution frequency of bone marrow cell subsets is similar for Cxcr4+/o compared to
Cxcr4+/+ donor-derived cell populations. Each data point represents ten mice presented as the mean ± SEM.
See also Figures S6 and S7.
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pattern of deletions and rearrangements, resulting for example
either in cancer, as previously reported (Jones and Jallepalli,
2012), or if the location of the event is fortuitous, in cure of a ge-
netic condition, as occurred in patient WHIM-09. Although it is
possible that deletion of the disease allele CXCR4R334X in the
original chromothriptic HSCof patientWHIM-09, which rendered
the cellCXCR4 haploinsufficient (CXCR4+/o), may have been suf-
ficient to repopulate the myeloid lineage—as suggested by the
strong HSC engraftment advantage of Cxcr4 haploinsufficient
mouse bonemarrow cells in our competitive bonemarrow trans-
plantation experiments—other factors, particularly haploinsuffi-
ciency for one or more of the 163 other genes that were deleted
by chromothripsis, may also have contributed. In this regard, at
least three of the other 163 deleted genes, DNMT3A (Challen
et al., 2012), MYCN (Laurenti et al., 2008), and IL1R (Orelio
et al., 2009), have been reported to regulate hematopoiesis
(Table S1).
That Cxcr4 haploinsufficiency should provide a competitive
engraftment advantage to HSCs is somewhat counterintuitive
since Cxcr4 has been well-documented to promote HSC hom-
ing to and retention in bone marrow (Broxmeyer et al., 2003a,
2003b, 2005; Dar et al., 2006; Kawai et al., 2007; Nie et al.,
2008; Sugiyama et al., 2006). However, it has also been re-
ported that CXCL12 secreted by CXCL12-abundant reticular
(CAR) cells that contact HSCs in the bone marrow niche is
able to enhance HSC quiescence by stimulating CXCR4
signaling (Nie et al., 2008; Sugiyama et al., 2006). The overall
effect on engraftment of reducing signaling via CXCR4 haploin-
sufficiency has not been previously tested in vivo and cannot
be confidently predicted given the diverse and contrasting
roles of the receptor on HSCs as well as on mature leukocytes.
Our mouse data confirmed in vivo that Cxcr4 haploinsuffi-
ciency enhanced HSC proliferation while maintaining long-
term hematopoiesis, therefore a competitive advantage
acquired from enhanced proliferation and potentially other
mechanisms by these cells may supercede any potential
disadvantage they may have at the level of bone marrow reten-
tion and homing.
Additional work using more stringent engraftment protocols in
mice and ultimately gene editing/transplantation trials in humans
will be needed to precisely determine the impact of CXCR4 hap-
loinsufficiency on HSC engraftment as well as on each of the pa-
rameters that regulate the physiologic steady-state levels of
mature leukocytes and hematopoietic stem and progenitor cells
in blood, bone marrow, and other hematopoietic compartments.
Such studies may further elucidate precisely how patient
WHIM-09 was cured, which may point to general applications
in transplantation and gene therapy.
EXPERIMENTAL PROCEDURES
Patients
Consistent with the Declaration of Helsinki, all human subjects signed
informed consent to participate in NIAID Institutional Review Board-approved
clinical protocols. All subjects were studied at the NIH Clinical Center.
Human Leukocyte Analysis
Leukocyte subsets were isolated from blood and bone marrow. PBMCs
and bone marrow cells were cultured ex vivo to expand CD34+ hematopoieticprogenitor cells and to generate BFU-E colonies. PBMCs were used to create
lymphoblastoid cell lines (LCL) from Epstein-Barr virus (EBV)-transformed B
cells.
Genetic Analysis
BstUI PCR-RFLP analysis was performed as previously described (Hernandez
et al., 2003) using patient genomic DNA. The genome was also analyzed by
PCR using primers spanning chromothriptic junctions of the derivative chro-
mosome 2 of patient WHIM-09; by Sanger method sequencing; by standard
cytogenetics and fluorescence in situ hybridization (FISH) of metaphase
chromosomes (Quest Diagnostics) using Abbott Molecular probes (Abbott
Molecular); by microarray analysis using the Affymetrix Cytoscan HD array
(Affymetrix); and by whole genome sequencing (WGS). For WGS, paired-end
patient WHIM-09 fibroblast and neutrophil DNA libraries were prepared using
the TruSeq DNA protocol (Illumina) and were sequenced using a HiSeq 2000
next generation sequencer (Illumina) generating 380 million reads per library
of 2 3 100 bp paired-ends. Reads were mapped to build hg19 of the human
genome to identify fusion junctions present in the neutrophil but not in the
fibroblast samples.
Transplantation Experiments
Cxcr4 floxed mice (Strain 008767, B6.129P2-Cxcr4tm2Yzo/J) and EIIa promoter
driven Cre recombinase transgenic mice (Strain 003724, B6.FVB-Tg(EIIa-cre)
C5379Lmgd/J) were obtained from the Jackson Laboratory and bred together
to generate Cxcr4+/o mice on a homozygous CD45.2 background. Cxcr4+/+
mice were obtained from Jackson Laboratory on the homozygous CD45.1
and homozygous CD45.2 backgrounds. Creation of WHIM knockin mice
bearing a heterozygous Cxcr4S338X mutation has been previously described
(Balabanian et al., 2012), and sperm from these mice were used for in vitro
fertilization at NIH to impregnate female C57BL/6 mice from Taconic Farms
to produce Cxcr4+/S338X on a homozygous CD45.2 background. Both
Cxcr4+/o and Cxcr4+/S338X mice on the homozygous CD45.2 background
were bred to Cxcr4+/+mice on a homozygous CD45.1 background to produce
Cxcr4+/o and Cxcr4+/S338X mice on a heterozygous CD45.1/CD45.2 back-
ground. In this way, differentially marked donor bone marrow cells could be
tracked in vivo during competitive transplantation experiments. Five million
bonemarrow cells (50% from each donor) were transferred via tail vein injec-
tion into recipient mice that had undergone lethal irradiation (900 rads) 8 hr
prior to transplant. The mice were fed with neomycin water for 4 weeks
post-irradiation. All animal experiments were performed using an NIAID Animal
Care and Use Committee (ACUC) approved protocol in approved and certified
facilities.
For additional details, see Extended Experimental Procedures.ACCESSION NUMBERS
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